Theriva Biologics, Inc.
TOVX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $12 | $14 | $12 | $8 |
| G&A Expenses | $7 | $7 | $7 | $6 |
| SG&A Expenses | $7 | $8 | $8 | $6 |
| Sales & Mktg Exp. | $0 | $1 | $1 | $0 |
| Other Operating Expenses | $7 | -$1 | $2 | $0 |
| Operating Expenses | $26 | $21 | $22 | $14 |
| Operating Income | -$26 | -$21 | -$22 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $0 | $0 |
| Pre-Tax Income | -$26 | -$20 | -$21 | -$14 |
| Tax Expense | $0 | -$2 | -$1 | $0 |
| Net Income | -$26 | -$18 | -$20 | -$14 |
| % Margin | – | – | – | – |
| EPS | -19.03 | -28.49 | -32.66 | -1.9 |
| % Growth | 33.2% | 12.8% | -1,618.9% | – |
| EPS Diluted | -19.03 | -28.48 | -32.66 | -1.9 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 12 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$19 | -$22 | -$19 | -$14 |
| % Margin | – | – | – | – |